In peptic ulcer therapy the search ends here



Prescribing Information

Presentation: Antepsin Tablets 1 gram are white, oblong, biconvex, uncoated tablets scored and engraved 1239 on one side and Ayerst on the other. Each tablet contains 1 gram sucralfate, a basic aluminium salt of sucrose octasulphate. **Uses:** For the treatment of duodenal ulcer, gastric ulcer and chronic gastritis. **Dosage and Administration:** For oral administration. Adults – Usual dose 1 gram 4 times a day to be taken one hour before meals and at bedtime. Maximum daily dose 8 grams. Four to six weeks treatment is usually needed for ulcer healing but up to twelve weeks may be necessary in resistant cases. Antacids may be used as required for relief of pain, but should not be taken half an hour before or after Antepsin. Elderly – There are no special dosage requirements for elderly patients but as with all medicines the lowest effective dose should be used. Children – Safety and effectiveness in children have not been established. **Contra-Indications, Precautions, Warnings, etc.** *Contra-indications:* There are no known contra-indications. *Precautions:* 1. The product should only be used with caution in patients with renal dysfunction. 2. Although animal reproductive studies show no evidence of foetal malformations, safety in pregnant women has not been established and Antepsin should be used during pregnancy only if clearly needed. 3. It is not known whether this drug is excreted in human milk. Caution should be exercised when Antepsin is administered to a nursing woman. *Drug Interactions:* Concomitant administration of Antepsin may reduce the bio-availability of certain drugs as has been observed in animal studies with tetracycline, phenytoin and cimetidine, and in human studies with digoxin. Administration of Antepsin with any of these drugs should be separated by two hours. Since Antepsin may hinder warfarin absorption, caution should be exercised when these two drugs are used together. *Side Effects:* A low incidence of mild side effects, e.g. constipation, has been reported. *Overdosage:* There is no experience in humans with overdosage. Acute oral toxicity studies in animals, however, using doses up to 12g/kg body weight, could not find a lethal dose. Risks associated with overdosage should, therefore, be minimal. **Pharmaceutical Precautions:** No special requirements for storage are necessary. **Legal Category:** POM. **Package Quantities:** Antepsin 1 gram – Securitainers of 100. **Product Licence Numbers:** PL No. 0607/0045. PA No. 149/4/2. **Basic N.H.S. Price:** Average daily cost 50p.

*ANTEPSIN is a registered trade mark

Further information is available on request to the Company

Date of preparation January 1985

Ayerst International

Ayerst Laboratories Ltd.
South Way, Andover, Hampshire SP10 5LT
Telephone: Andover (0264) 58711

Distributors in Ireland: Ayerst Laboratories Ltd.
765 South Circular Road, Islandbridge, Dublin 8

Gastrozepin is a selective antimuscarinic agent which provides balanced control of gastric secretion without markedly affecting other peripheral receptor sites. This gastro-selective action means that, in practice, Gastrozepin is a well-tolerated drug which heals peptic ulcers.

Gastrozepin DOES NOT . . .
- **rely on acid reduction alone**
- **rely on pepsin reduction alone**
- **rely on mucosal protection alone**
- **profoundly affect intragastric pH**

Gastrozepin DOES . . .
- **relieve daytime pain**
- **relieve night-time pain**
- **reduce antacid intake**
- **heal peptic ulcers with one 50 mg tablet b.d.**

For the treatment of peptic ulcer

Twice daily

GASTRO SELECTIVE

Gastrozepin®

pirenzepine

The gastro-selective anti-secretory

Prescribing Information; Presentation: White tablets each containing 50 mg of pirenzepine dihydrochloride scored on one face with "G" on one side of the score, and "50" on the other. The obverse is impressed with the symbol. **Uses:** Gastrozepin is indicated in the treatment of gastric and duodenal ulcers. **Dosage:** 50 mg at bedtime and in the morning before meals. In severe cases the total daily dose may be increased to 150 mg in divided doses. Continuous therapy may be recommended for up to three months. **Contra-indications, Warnings etc:** Interaction with sympathomimetics and monoamine oxidase inhibitors and Gastrozepin is a theoretical possibility. Gastrozepin is not recommended during pregnancy although in animal experiments no teratogenic effects were noted. Breast milk concentration after therapeutic doses is unlikely to affect the infant. *Side effects:* occasionally transitory dry mouth and accommodation difficulty may occur. Treatment of overdosage: entirely symptomatic. There is no specific antidote. **Basic NHS price:** 50 mg tablets, 60 £20.50. **Product Licence No.:** 50 mg tablets, PL0014/0260.

Further information is available on request.
The Boots Company PLC, Nottingham.

Gastrozepin™ Trade Mark

HEALING POWER WHEN IT'S NEEDED MOST IN DUODENAL ULCER



Acid attack at night is now known to be one of the most important factors in the formation of duodenal ulcers.

'Tagamet' 800 mg at bedtime effectively controls this damaging nocturnal acid without disturbing the patient's normal daytime gastric physiology.

One 'Tagamet' 800 mg tablet at bedtime for four weeks is the recommended healing regimen for all duodenal ulcer patients.

And the results are impressive... 'Tagamet' 800 mg completely healed 79 per cent of duodenal ulcers in four weeks and 96 per cent in eight weeks[1] whilst providing prompt and effective relief from both daytime and night-time pain.

With 'Tagamet' 800 you can offer your patients healing power precisely when it's needed.

TAGAMET
CIMETIDINE 800

One tablet at bedtime for four weeks

Reference 1. Lambert R. In: 'Tagamet.' New Dimensions. A Symposium Proceedings. XII Int Cong Gastroenterol, Lisbon, 1984;15-23.

Prescribing Information. Presentations 'Tagamet' Tablets, each containing 800 mg cimetidine (PL 0002/0128: 28 tablets, £15.78) or 400 mg cimetidine (PL 0002/0092: 56 tablets, £16.61). 'Tagamet' Syrup, containing 200 mg cimetidine per 5 ml (PL 0002/0073: 500 ml, £19.20). **Indication** Duodenal ulcer. **Dosage** *Usual dosage: Adults. Duodenal ulcer,* 800 mg once a day at bedtime, or 400 mg b.d. with breakfast and at bedtime. To prevent relapse, 400 mg at bedtime or 400 mg morning and at bedtime. *Elderly:* As above unless markedly impaired renal function. *N.B. For full dosage instructions see Data Sheet.* **Cautions** Impaired renal function: reduce dosage (see Data Sheet). Potentiation of oral anticoagulants, phenytoin and theophylline (see Data Sheet).



Prolonged treatment: observe patients periodically. Potential delay in diagnosis of gastric cancer (see Data Sheet). Care in patients with compromised bone marrow (see Data Sheet). Avoid during pregnancy and lactation. **Adverse reactions** Diarrhoea, dizziness, rash, tiredness. Gynaecomastia, occasional reversible liver damage, confusional states (usually in the elderly or very ill). Very rarely interstitial nephritis, acute pancreatitis, thrombocytopenia, headache, myalgia, arthralgia; very rare reports of alopecia, reversible impotence but no causal relationship established at usual therapeutic doses. **Legal category** POM. 4.3.85.
Smith Kline & French Laboratories Limited, Welwyn Garden City, Hertfordshire AL7 1EY.

SK&F

TG:AD1265



PROVEN: Equal efficacy. PROVEN: Superior quality of life.

Although much has been published on the comparative efficacy and patient acceptance of COLIFOAM, the literature has until now lacked a comparison against prednisolone enemas.

That study has now been published.

The verdict? COLIFOAM is equal in efficacy to prednisolone enemas in the treatment of distal inflammatory bowel disease, but causes significantly less interference in patients' daily lives[1].

Analysis of the disturbance in social, sexual, occupational and routine outdoor activities all revealed statistically significant differences in favour of COLIFOAM.

COLIFOAM is also easier to retain than steroid enemas[1,2,3]. Retrograde spread has been shown to increase with the extent of disease[4] and COLIFOAM can reach well into the descending colon[5].

In distal inflammatory bowel disease. A better choice every time.

References (1) Somerville KW et al. (in press). (2) Ruddell WSJ et al. Gut 1980; 21:885-889. (3) Gaucher P and Champignuelle B. Journal Gastroenterol. Francais 1983;193:35. (4) Farthing MGJ et al. British Medical Journal 1979; 2:822-824. (5) Rhodes JM. Journal of Clinical & Hospital Pharmacy 1983;8:219-232. Prescribing Information. Presentation White odourless aerosol foam containing hydrocortisone acetate PhEur 10%. Uses Anti-inflammatory corticosteroid therapy for the topical treatment of ulcerative colitis, proctosigmoiditis and granular proctitis. Dosage and administration One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use, (illustrated instructions are enclosed with every pack). Satisfactory response usually occurs within five to seven days. Contra-indications, warnings etc. Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. Pharmaceutical precautions Pressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not pierce or burn even after use. Do not refrigerate. Shake vigorously before use. Keep out of reach of children. For external use only. Legal category POM. Package quantities Aerosol canister containing 25g. (approx. 14 applications) plus a plastic applicator and illustrated leaflet. Basic NHS cost 25g plus applicator, £7.25. Further Information One applicatorful of Colifoam provides a dose of approximately 125mg of hydrocortisone acetate, similar to that used in a retention enema, for the treatment of ulcerative colitis, sigmoiditis and proctitis. Product Licence No. 0036/0021. Further information is available on request. Stafford-Miller Ltd., Professional Relations Division, Hatfield, Herts. AL10 0NZ.

Not 'All gas and flatus'

In Irritable Bowel Syndrome

colofac®

mebeverine

Blessed relief

Colofac is also indicated for the relief of gut spasm secondary to diverticular disease.

PRESCRIBING INFORMATION. PRESENTATION: White, sugar-coated tablets each containing 135 mg mebeverine hydrochloride. Available in packs of 100. Basic NHS price £8.35. INDICATIONS: 1. Irritable Bowel Syndrome. 2. Gastro-intestinal spasm secondary to organic diseases. DOSAGE AND ADMINISTRATION: Adults and children ten years and over: One tablet three times a day, preferably 20 minutes before meals. CONTRA-INDICATIONS, WARNINGS, ETC: Animal experiments have failed to show any teratogenic effects. However, the usual precautions concerning the administration of any drug during pregnancy should be observed. PRODUCT LICENCE NO: 512/0044.

duphar

Further information is available upon request to the company.
Duphar Laboratories Ltd, Duphar House, Gaters Hill, West End, Southampton SO3 3JD. Tel: (0703) 472281

Created by Nature. Proven by Science.

For relief of irritable bowel and abdominal pain

The unique enteric-coated Colpermin capsule is a long-acting, slow-release product containing a thixotropic paste of peppermint oil. The enteric coating permits this naturally occurring medication to be delivered direct to the distal small bowel. Recent studies confirm that Colpermin offers direct relief to the patient by effectively relaxing intestinal smooth muscle to relieve colonic pain and gaseous distension.

- Irritable bowel symptoms are highly responsive to placebo, but in a recent double-blind cross-over trial, Colpermin was found to be superior to placebo in alleviating irritable bowel symptoms over a three-week period.[1]

- A delayed-release preparation, Colpermin reaches the colon in an unmetabolised state, allowing it to effectively reduce colonic motility.[2]

- Recent ultrasound studies show a consistent inhibitory effect of topical peppermint oil on colon motility and symptomatic improvement of irritable bowel patients given peppermint oil.[3]

References:

1. Rees WDW, Evans BK, Rhodes J: Treating irritable bowel syndrome with peppermint oil. *Br Med J* 2:835-836, 1979.

2. Somerville KW, Richmond CR, Bell GD: Delayed release peppermint oil capsules (Colpermin) for the spastic colon syndrome: A pharmacokinetic study. Proceedings of the British Pharmacological Society, Cambridge, April 1983. *Br J Clin Pharmacol*, to be published.

3. Taylor BA, Duthie HL, Oliveira RB, et al: Ultrasound used to measure the response of colonic motility to essential oils. Proceedings of *The International Motility Symposium* Aix-en-Provence, France, September 1983, to be published.

COLPERMIN™

(enteric-coated peppermint oil) CAPSULES



PRESCRIBING INFORMATION

Presentation: Enteric-coated gelatin capsule. Each contains 0.2 ml standardised peppermint oil B.P., Ph. Eur. **Uses:** For the treatment of symptoms of discomfort and of abdominal colic and distension experienced by patients with irritable bowel syndrome. **Dosage and Administration:** One capsule three times a day, preferably before meals and taken with a small quantity of water. The capsules should *not* be taken immediately after food. The dose may be increased to two capsules, three times a day when discomfort is more severe. The capsules should be taken until symptoms resolve, usually within one or two weeks. At times when symptoms are more persistent, the capsules can be continued for longer periods of between 2 to 3 months. There is no experience in the use of these capsules in children under the age of 15 years.

Tilotts LABORATORIES

Contraindications, Warnings, etc. Precautions: The capsule should not be broken or chewed. Patients who already suffer from heartburn, sometimes experience an exacerbation of these symptoms when taking the capsule. Treatment should be discontinued in these patients. **Adverse effects:** Heartburn, sensitivity reactions to menthol which are rare, and include erythematous skin rash, headache, bradycardia, muscle tremor and ataxia. **Product Licence:** PL 0424/0009. **Basic NHS Cost:** £10.58 per 100. UK and Foreign Patents pending. Colpermin is a trade mark of Tillotts Laboratories. Further information is available from Tillotts Laboratories, Henlow Trading Estate, Henlow, Beds.
European Patent No. 0015334. **UK Patent No. 2006011.**

Henlow Trading Estate, Henlow, Beds. SG16 6DS

Therapeutic Endoscopy Specifically

Upper GI bleeders

Effective, safe and appropriate therapy for ALL patients

The management of upper GI bleeders has been dramatically improved with the introduction of KeyMed's new therapy system - the Olympus GIF-IT10 OES OGD endoscope, KeyMed TVD-1 Transendoscopic Vascular Detector and Olympus Heat Probe. The GIF-IT10, with its large 3.7mm channel allows passage of the TVD-1 or Heat Probe, with simultaneous powerful suction and its integral water jet enables easy washing of any suspicious areas without the complication of passing washing pipes. The ultrasound probe of the TVD-1 uses the Doppler effect to map vascular pathways, allowing the endoscopist to accurately predict the likelihood of rebleeding and therefore prescribe effective therapy. If transendoscopic haemostasis is required, the Heat Probe is both safe and effective in controlling bleeding.



TVD-1
Probe Tip

Heat Probe
Tip

Try the system for yourself — for a demonstration, call our Medical Customer Liaison Department.

OLYMPUS

KEYMED

Specialised Services to Medicine

KeyMed (Medical & Industrial Equipment) Ltd.
KeyMed House, Stock Road, Southend-on-Sea, SS2 5QH.
Telex: 995283, Telefax: (0702) 65677, Tel: (0702) 616333.

KeyMed (Ireland) Ltd.
KeyMed House, Lord Edward Court,
Bride Street, Dublin 8.

KeyMed Inc.
400 Airport Executive Park,
Spring Valley, New York, 10977.

Enteric coated granules for improved enzyme delivery in pancreatic insufficiency

Creon®

pancreatin

- **Capsule dissolves in stomach**
- **Granules unaffected by stomach acid**
- **Enzymes released in duodenum**
- **Mimics the normal digestive process**

A new release for patients with pancreatic insufficiency

PRESCRIBING INFORMATION: Presentation: Brown/yellow capsules containing enteric coated granules of pancreatin equivalent to: 9,000 BP units of amylase, 8,000 BP units of lipase, 210 BP units of protease. Available in packs of 100. Basic NHS price £13.33. **Indication:** Pancreatic exocrine insufficiency. **Dosage and administration:** Adults and children: Initially one or two capsules with meals, then adjust according to response. The capsules should be swallowed whole, without chewing, with a little fluid, during the meal. **Contra-indications, Warnings, etc. Contra-indications:** Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. **Warnings:** Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin. Rarely cases of hyper-uricosuria and hyper-uricaemia have been reported with high doses of pancreatin. Overdosage could precipitate meconium ileus equivalent. Perianal irritation could occur, and, rarely, inflammation when large doses are used. **Product Licence Number** 5727/0001.

duphar Further information is available from:
Duphar Laboratories Ltd, Duphar House, Gaters Hill, West End, Southampton SO3 3JD. Tel: (0703) 472281

Therapeutic Endoscopy Specifically

NEW Olympus CF-IT10L therapeutic OES colonoscope with ultra-large channel.

Dramatically improved suction through massive 4.2mm channel.
Quickly removes bowel residue in poorly prepared patients, even with accessories in place. Superb optics with large, bright, sharp images, but NO COMPROMISE on insertion tube characteristics — a slim outer diameter, and subtle two-stage flexibility, with improved torque stability giving even better ease of insertion.
Try it for yourself — for a demonstration, contact our Medical Customer Liaison Department.



Specification	
Outer diameter	13.8mm
Channel diameter	4.2mm
Angulation	180° up/180° down 160° left/160° right Max. 230°
Working length	1680mm
Field of view	120°

KEYMED
Specialised Services to Medicine

KeyMed (Ireland) Ltd.
KeyMed House, Lord Edward Court,
Bride Street, Dublin 8.

The Focus of Medical Technology.

As the medical profession searches tirelessly for the means to further the investigation and treatment of conditions which have so far eluded it, there is one company motivated towards helping achieve that end.

The company is Pilkington Medical Systems. Their expertise in electro-optical systems as manufacturers of medical lasers and endoscopes combined with the considerable research and development capability has positioned them as one of the world's foremost medically innovative companies.

So, as the world looks for the next healthcare breakthrough, the medical profession can look to Pilkington Medical Systems – the focus of medical technology.

PILKINGTON

◄ Medical Systems ►

NEW

ANNOUNCING

ASACOL™

(MESALAZINE)

"This preparation is an important advance in the management of colitis since it may be given to patients unable to take sulphasalazine. . . ."[1]

For full prescribing information see overleaf

Tillotts LABORATORIES

NEW

ASACOL™

(MESALAZINE)

For the maintenance of remission in patients with ulcerative colitis who cannot tolerate sulphasalazine.

Asacol delivers only 5-amino salicylic acid and is effective in maintaining clinical remission in patients with ulcerative colitis[1].

Asacol provides efficacy comparable to sulphasalazine, but with considerably less side effects[3].

Asacol tablets have a patented acrylic-based resin coating that enables them to remain intact until all the active ingredient is released in the colon[2].

Asacol is specifically recommended for ulcerative colitis patients who have difficulty tolerating sulphasalazine.

Mesalazine is the British-approved name for 5-amino salicylic acid.



Radiograph taken five hours after convalescent patients ingested Asacol in capsule form containing barium, showing them to be intact in the terminal ileum.[2]

Radiograph of the same patient after eight hours, showing broken capsules in the ascending colon.

References:

1. Dew MJ, Hughes P, Harries AD, et al: Maintenance of remission in ulcerative colitis with oral preparation of 5 aminosalicylic acid. *Br Med J* 285:1012-1014, 1982.

2. Dew MJ, Hughes PJ, Lee MG, et al: An oral preparation to release drugs in the human colon. *Br J Clin Pharmacol* 14:405-408, 1982.

3. Dew MJ, Harries AD, Evans BK, Rhodes J, et al: Treatment of ulcerative colitis with oral 5-aminosalicylic acid in patients unable to take sulphasalazine. *The Lancet* October 1, 1983 p.801.

ABBREVIATED PRESCRIBING INFORMATION

PRESENTATION
Red tablets containing 400mg of mesalazine (5-amino salicylic acid) coated for release in the terminal ileum and colon.

USES
For the maintenance of remission of ulcerative colitis in patients who cannot tolerate sulphasalazine.

DOSAGE AND ADMINISTRATION
Adults: 3 to 6 tablets daily in divided doses
There is no dose recommendation for children.

CONTRA-INDICATIONS, WARNINGS, ETC.
Contra-Indications
Contra-indications: a history of sensitivity to salicylates. Children under 2 years of age
Precautions
Renal disorder. Mesalazine is excreted rapidly by the kidney mainly as its metabolite, N acetyl 5-amino salicylic acid. In rats large doses of mesalazine injected intravenously produce tubular and glomerular toxicity. Although no renal toxicity has been reported in patients taking Asacol, it is not recommended in patients with renal impairment and caution should be exercised in patients with a raised blood urea or proteinuria.
Asacol should not be given with lactulose or similar preparations which lower stool pH and may prevent release of mesalazine.
Adverse Reactions
Adverse reactions occur in a small proportion of patients who previously could not tolerate sulphasalazine. The side effects are predominantly gastrointestinal (nausea, diarrhoea and abdominal pain) and headache. Asacol may be associated with the exacerbation of the symptoms of colitis in those patients who have previously had such problems with sulphasalazine.
Other side effects observed with sulphasalazine such as depression of bone marrow and of sperm count and function, have not been reported with Asacol.

LEGAL CATEGORY: POM
PL: 0424/0032
Basic NHS Price: £21.85/100 tablets

U.K. Patent No. 8322387

Tillotts LABORATORIES

Henlow Trading Estate, Henlow, Beds. SG16 6DS.

Sigmoidoscopes: Take a Good Look at the Alternative.

- Fuji are the largest photo optical company in the world.
- Fuji's immense research and development resources have resulted in instruments which are second-to-none.
- Fuji Sigmoidoscopes are guaranteed for 18 months, including accidental damage within the first 12 months.
- Fuji Sigmoidoscopes are serviced by Pyser Ltd, – an established UK company with 50 years' experience in sophisticated optical systems.
- Pyser's factory trained service engineers always deliver on time – no ifs or buts.
- Pyser staff are efficient, courteous and friendly – we never take our customers for granted.

FUJINON

Fujinon Fibrescopes
Pyser Ltd., Fircroft Way,
Edenbridge, Kent TN8 6HA.
Edenbridge (0732) 864111 (8 lines)

Therapeutic Endoscopy Specifically

NEW Olympus TJF-10 OES duodenoscope for advanced biliary therapy.

4.2 mm channel for 12Fr stents and effective lithotripsy.
The TJF-10 opens up new horizons in biliary therapy. The ultra-large channel means a wide range of accessories can be used, including many new devices for biliary drainage and stone destruction currently under development.
The retro-viewing optical system, with its large, clear images, allows easier placement of therapeutic devices, and unparalleled photographic and CCTV results.
All channels are accessible for thorough cleaning and the entire instrument can be fully immersed in disinfectant — of paramount importance for both improving the instrument's reliability and reducing the risk of patient infection.



Try it for yourself — for a demonstration, contact our Medical Customer Liaison Department.

Papilla of Vater

12 Fr stent

Specification	
Outer diameter	12.5mm
Channel diameter	4.2mm
Angulation	120° up/90° down 110° right/90° left
Working length	1240mm
Field of view	80°
Direction of view	Side viewing, 5° retro

OLYMPUS

KEYMED
Specialised Services to Medicine

KeyMed (Medical & Industrial Equipment) Ltd.
KeyMed House, Stock Road, Southend-on-Sea, SS2 5QH.
Telex: 995283, Telefax: (0702) 65677, Tel: (0702) 616333.

KeyMed (Ireland) Ltd.
KeyMed House, Lord Edward Court,
Bride Street, Dublin 8.

KeyMed Inc.
400 Airport Executive Park,
Spring Valley, New York, 10977.

SALAZOPYRIN® EN

sulphasalazine

HAS TOLERABILITY ALL WRAPPED UP

"Patients in whom sulfasalazine induces dyspeptic symptoms alone can be given EN Salazopyrin (entero-soluble) instead, and no more than 5% of these patients will be so troubled by dyspepsia that the treatment has to be discontinued."
Nielsen, O.H., Scand. J. Gastroenterol., 1982, 17, 389



Get them into the SALAZOPYRIN habit

DAY AFTER DAY AFTER YEAR

500mg q.i.d. in ulcerative colitis

PRESCRIBING INFORMATION

Dosage and Administration Plain or EN Tabs: In acute moderate attacks 2-4 tablets 4 times a day. In severe attacks give steroids also. Gradually reduce dose after 2-3 weeks to 3-4 tabs/day, given indefinitely. Suppositories: Two morning and night reducing dose after 3 weeks with improvement. Enema: One to be given at bedtime. Preparation contains adult dose. Children: Reduce adult dose on basis of bodyweight.

Contra-indications Sensitivity to salicylates and sulphonamides. Infants under 2 years. Enema: Sensitivity to parabens.

Adverse Reactions Side effects common to salicylates or sulphonamides may occur. Most commonly these are nausea, loss of appetite and raised temperature which may be relieved on reduction of dose; use of EN tablets, enema or suppositories. If serious reactions occur the drug should be discontinued. Rare Adverse Reactions: Haematological: haemolytic anaemia, agranulocytosis, aplastic anaemia. Hypersensitivity: eg rash, fever. Gastrointestinal: eg stomatitis, impaired folate uptake. C.N.S.: eg peripheral neuropathy. Fertility: eg reversible oligospermia. Renal: eg proteinuria, crystalluria. Also: Stevens-Johnson syndrome and lung complications, eg fibrosing alveolitis.

Precautions Care in porphyria, allergic, renal or hepatic disease. Glucose 6-PD deficiency. Blood checks initially and periodically.

Pregnancy and Lactation While the ingestion of drugs in these situations may be undesirable, the severe exacerbations of the disease which can occur commends the continuance of therapy. Long clinical usage and experimental studies have failed to reveal teratogenic or icteric hazards. The amounts of drug present in the milk should not present a risk to a healthy infant.

Packages and Prices Plain Tablets (0·5g) 100 & 500: £6·70 for 100. EN Tablets (0·5g): 100 & 500: £8·70 for 100. Suppositories (0·5g): 10 & 50: £2·80 for 10. Enemas (3·0g): 7: £12·10 for 7.
Product Licence Numbers Plain Tablets 0009/5006. EN Tablets 0009/5007. Suppositories 0009/5008. Enema 0009/5009.

Pharmacia

Further information is available on request
Pharmacia Limited, Pharmacia House
Midsummer Boulevard, Milton Keynes MK9 3HP
Telephone Milton Keynes (0908) 661101